Assessment of general characteristics of patients with primary metastatic breast carcinoma: single center experience

Basit Öğe Kaydı
dc.authorid0000-0001-7306-5233en_US
dc.authorid0000-0001-5279-0903
dc.authorid0000-0002-6839-2632
dc.authorid0000-0002-2756-8646
dc.contributor.authorÜyeturk, Ümmügül
dc.contributor.authorBudakoğlu, Burçin
dc.contributor.authorTürker, İbrahim
dc.contributor.authorHelvacı, Kaan
dc.contributor.authorSönmez, Özlem Uysal
dc.contributor.authorAktaş, Gülali
dc.contributor.authorArslan, Ülkü Yalçıntaş
dc.contributor.authorÖksüzoğlu, Ömür Berna Çakmak
dc.date.accessioned2021-06-23T19:34:12Z
dc.date.available2021-06-23T19:34:12Z
dc.date.issued2013
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: Breast cancer (BC) is a heterogeneous disease. Several subgroups have been identified, according to the clinical presentation and radiographic, pathological, biological, and molecular characteristics of the tumor. Intrinsic genetic heterogeneity may be responsible for these differences. To date, little is known about the clinical features and outcome of patients with primary metastatic BC (PMBC) defined as those presenting with stage IV disease. Material and methods: Between September 2007 and May 2011, BC patients who were admitted to a clinic were assessed. Patients with PMBC were included in this retrospective analysis. The patients' demographic characteristics, treatment schedules, and survival data were recorded. Results: Of 2478 BC patients, 102 (4.1%) with PMBC were included in the analysis. The median age of the patients was 50 (26-90) years. Only four patients (3.9%) had previously undergone mammography. The median progression-free survival (PFS) and overall survival (OS) were 30 and 66 months, respectively. The PFS and OS were unaffected by age, menopausal status, ECOG, histology, or tumor grade. Both PFS and OS were affected by HR status (log rank p = 0.006, log rank p = 0.04), HER2 status (p = 0.001, p = 0.005), site of metastasis (p = 0.01, p = 0.04), radiotherapy (p = 0.04, OS p = 0.03), and bisphosphonate treatment (p = 0.02, p = 0.006). PFS was greater in the hormone therapy group (43 months, p = 0.03) while OS was greater in the patients that received chemotherapy (76 months, p = 0.01). Conclusions: Mammography should be given greater emphasis, considering its importance in the prevention of PMBC. As a treatment option for bone and soft tissue metastatic PMBC patients, hormone therapy should be effective as a first-line treatment.en_US
dc.identifier.doi10.5114/wo.2013.37543
dc.identifier.endpage455en_US
dc.identifier.issn1428-2526
dc.identifier.issn1897-4309
dc.identifier.issue5en_US
dc.identifier.pmid24596535en_US
dc.identifier.startpage450en_US
dc.identifier.urihttps://doi.org/10.5114/wo.2013.37543
dc.identifier.urihttps://hdl.handle.net/20.500.12491/7421
dc.identifier.volume17en_US
dc.identifier.wosWOS:000331422300008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÜyeturk, Ümmügül
dc.institutionauthorAktaş, Gülali
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofWspolczesna Onkologia-Contemporary Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPrimary Metastatic Breast Carcinomaen_US
dc.subjectDemographic Characteristicsen_US
dc.subjectMammographyen_US
dc.subjectFactors Affecting Survivalen_US
dc.titleAssessment of general characteristics of patients with primary metastatic breast carcinoma: single center experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
ummugul-uyeturk-7421.pdf
Boyut:
115.6 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu